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Introduction: Antipsychotic medication (APM) initiation is associated with rapid and
substantial weight-gain and high rates of obesity. Obesity leads to premature onset of
cardiometabolic diseases and contributes to the 15–20 year shortfall in life expectancy
in those experiencing severe mental illness. Dietary energy intake excess is critical to
weight management but is yet to be quantified in youth with first episode psychosis (FEP)
receiving APM. This study aimed to describe the degree of energy overconsumption and
the food sources contributing to this in youth with FEP.
Materials andMethods: People aged 15–30 years with FEP receiving APM completed
diet histories through qualified dietitians to assess energy imbalance and food sources.
Outcome measures were: (i) energy balance; and (ii) intake of core and discretionary
foods.
Results: Participants (n = 93) were aged 15–29 years (mean = 21.4 ± 2.9 years)
and exposed to APMs for a median for 8 months (Interquartile Range (IQR) 11 months).
Energy balance was exceeded by 26%, by a median 1,837 kJ per day (IQR 5,365 kJ).
APM polypharmacy and olanzapine were linked to larger excesses in dietary energy
intake. The greatest contributors to energy intake were refined grain foods (33%) and
discretionary foods (31%).
Conclusion: Young people with FEP receiving APMs appear to havemarkedly excessive
energy consumption, likely contributing to rapid weight-gain, and thereby seeding
future poor physical health. Larger, prospective studies are needed to gain a greater
understanding of dietary intake, and its effects on health, in people with FEP.
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INTRODUCTION
People receiving antipsychotic medication (APM) for first-
episode of psychosis (FEP) experience rapid, excessive weight
gain and acquire risk factors for cardiometabolic disease (1, 2).
Weight-gain is most rapid in the first few months of APM
treatment, and accompanied by central obesity (3). Longitudinal
data shows that mean weight gain is 12 kg over the first 2 years
of APM treatment, increasing to a mean 19 kg over the first
4 years (4). The higher rates of abdominal obesity (OR 4.43),
hypertriglyceridemia (OR 2.73), metabolic syndrome (OR 2.35),
low HDL (OR 2.35), diabetes (OR 1.99), and hypertension (OR
1.36) compared to controls (5), culminates in a 20-year life
expectancy gap compared to the general population (6, 7). Each
of these drivers ill health are preventable lifestyle factors relating
to dietary intake.
A recent prospective study followed people from their first
episode of psychosis, and found that after 20 years, 62% of people
with schizophrenia and 50% of people with bipolar disorder
were obese, substantially higher than national averages (8).
Interestingly, those with SCZ gained significantly more weight
in the first 10 years compared to the subsequent 10 years,
whereas those with bipolar disorder gained less weight in the
first 10 years compared to years 10–20. Critically, this study
monitored weight change for 20 years, significantly longer than
other prospective studies, and showed for the first time that
weight gain may not being to plateau until between 10 and 20
years post first hospitalization. The authors also suggested that
participants could continue to gain weight, even after the 20-year
observation period.
Appropriate dietary energy intake is fundamental to
weight stability, management of weight excess, and managing
cardiometabolic risk. It is yet to be explored, however, in people
with FEP. APM are associated with increased appetite (9),
unhealthy dietary intake (10), disordered eating behaviors (11)
and sedentary behavior (reduced energy expenditure) (12),
however mechanisms are not clearly understood. Dopamine,
serotonin, muscarinic, and histamine receptors have all been
implicated in APM-induced hunger changes, with APM with a
high affinity for the 5-HT2C and muscarinic receptors associated
with the greatest risk for weight-gain (13). Evidence also suggests
weight-gain mechanisms innate to the psychiatric illness,
such as brain structural damages (14). The eating process in
those experiencing psychosis is made difficult due to impaired
executive functioning, which complicates restrained eating and
facilitates disinhibition (15). It appears that both drug-naïve and
those receiving APM treatment have insensitive rewards systems
shifting the preference to less nutritious foods high in sugar, salt,
and fat (14).
Whilst APM-induced changes in appetite, weight and obesity
have been well-documented, the energy intakes, food preferences
and dietary quality of youth with FEP receiving APM have
yet to be clearly quantitated. Limited published data highlight
unhealthy dietary habits in severe mental illness (10), with
diets lower in fruit and fiber, and higher intake of sweet
foods and drinks compared to the general population. Much
remains to be delineated, including quantitation of energy
excess, dietary quality, and shortfalls to national dietary
guidelines.
In addition to energy consumption, diet quality also
importantly contributes to health. Quality is inferred from the
inclusion of essential fatty acids, protein, vitamins, minerals, and
fiber, typically found in “core food groups” such as vegetables,
fruit, wholegrains, milk, cheese, and yogurt, and protein-rich
foods (meat, poultry, seafood, eggs, nuts, and legumes). On the
other hand, “discretionary foods” are low- or non- nutritious
foods typically found in “Westernized” diets, which are generally
high in added sugars, salt and/or fat, and are identified risk factors
for poor cardiometabolic health (16).
Understanding these food choices and preferences is
fundamental to the development of dietary strategies to reverse
and/or prevent APM-induced obesity in youth with psychosis.
To the authors’ knowledge no study has yet examined energy
intake relative to individual energy requirement in order to
estimate energy excess, in the early stage of APM-treatment
when weight gain occurs most rapidly. Further, comparisons of
diet quality against national standards are lacking.
AIMS OF THE STUDY
In youth with FEP receiving APM, this study aimed to (i) quantify
energy intake against energy requirements to determine the
degree of energy intake imbalance, and (ii) examine diet quality,
compared to Australian national dietary recommendations.
METHODS
Design
We undertook a cross-sectional analysis of dietary intake in
youth experiencing FEP. Inclusion criteria were: (i) 15–30
years of age, (ii) within 2 years of first onset of psychotic
symptoms, and (iii) receiving APM. Exclusion criteria were
having received dietary education and/or intervention since
commencing APM. The treating psychiatrists provided data
on psychotropic medications and Diagnostic and Statistical
Manual for Mental Disorders (DSM-V) diagnoses (17). This
study received ethical approval from the South Eastern Sydney
Local Health District Human Research Ethics Committee
(HREC ref no: 14/276; LNR/14/POWH/614). This study was
reported using the Strengthening the Reporting of Observational
Studies in Epidemiology–Nutritional Epidemiology (STROBE-
nut) guidelines (18).
Participants/Setting
Participants were patients who were referred, as part of routine
care, to the Keeping the Body in Mind program between January
2015 and December 2017, from three allied community youth
mental health services in urban Sydney. Keeping the Body
in Mind is a lifestyle program involving a dietitian, exercise
physiologist, and mental health nurse consultant, targeting the
physical health of people with mental illness. On referral to
the program, dietary intake was assessed by a dietitian using
a comprehensive diet history (19), accounting for usual intake
and variation. A food checklist was included to ensure all
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food categories were evaluated. Portion size was estimated
using food models and measuring cups. The frequency of
various foods was evaluated, including the typical composition
of meals (20). Individual diet histories were completed in a
private consulting room, over 30–60min. This dietary assessment
formed part of a broader cardiometabolic lifestyle assessment
(21), including anthropometric and physical activity measures
and was conducted prior to the delivery of Keeping the Body in
Mind intervention (22).
Outcome Measures
Estimated energy intake (EEI) was derived from kilojoule values
assigned to food groups described in the Australian Guide to
Healthy Eating (AGHE) (23). To determine energy balance,
estimated energy requirement (EER) was calculated for each
participant using the Schofield equation (24), adjusting for
physical activity level (sedentary 1.3–1.4x BMR, light-moderate
1.5–1.6x BMR, active 1.7–1.8x BMR) (25) and using adjusted
ideal body weight for participants with a body mass index
(BMI) ≥25 kg/m2 (see Supplementary Material 1) (26). Using
Goldberg et al. cut-off limit for plausible intake, participants were
considered to be underreporting if the EEI:BMR ratio was <0.9
(27).
Diet quality was measured by estimating serves of core food
groups: (i) vegetables (separately for starch and non-starch
vegetables), (ii) fruit, (iii) milk, cheese, yogurt, and alternatives,
(iv) grain foods, (v) protein foods such as meat, poultry, fish,
eggs, nuts and seeds, and (vi) discretionary foods as defined in the
AGHE (23). These estimated intakes of food group servings were
compared to the recommended serves, based on age and sex, also
defined in the AGHE (23). Grain foods were further categorized
into mostly wholegrain (≥50% wholegrain products) or refined
(<50% wholegrain products).
Weight (kg) was measured with participants barefoot in light
street clothing. Height (m) was measured using a stadiometer
with participants barefoot. Bodymass index (BMI) was calculated
using weight/ height x height, kg/m2. Waist circumference (cm)
was measured horizontally at the navel using a measuring tape
to the nearest 0.1 cm. BMI was categorized using the World
Health Organization classification (28). Central obesity was
categorized using waist circumference and the International
Diabetes Federation classification (29).
Statistical Analyses
We compared (i) estimated energy intake and recommended
energy intakes, and (ii) estimated food group intake and
recommended food group intakes. The Shapiro-Wilk test was
run as a test of normality. Paired sample and/or independent
samples t-tests were run to test for significance between variables
for normally distributed data, and reported as mean and
standard deviation. The Wilcoxon Signed Ranks Test was used
to test for statistical significance for non-normally distributed
data. Non-normally distributed data were reported as median
and range. Chi-squared tests examined the weight and waist
circumference status of participants. Kruskal-Wallis Tests with
Pairwise Comparisons were used for subgroup analyses of
excess energy intake by diagnosis and APM prescription. A
Spearman’s Rho correlation was run between excess energy
intake and: (i) chlorpromazine equivalents, and (ii) duration of
APM treatment. Statistical significance was set at p < 0.05. A
Bonferroni correction was incorporated for t-test comparisons
across multiple food groups, with a new statistical significance
level set at p < 0.007. Analyses were performed using SPSS
Version 24 (Chicago, IL, United States).
RESULTS
There were 93 participants (58 males, 62%), mean age 21.4 ± 2.9
years. Participants were predominantly Europids (n = 52, 56%)
and, in decreasing frequency, Asian (n= 27, 29%), Maori/Pacific
Islander (n = 6, 7%), Aboriginal/Torres Strait Islander (n = 3,
3%), Middle Eastern (n = 3, 3%), South American (n = 1, 1%),
and African (n = 1, 1%). DSM-V diagnoses were: schizophrenia
(n = 32), bipolar affective disorder (n = 16), psychosis not
otherwise specified (n = 15), major depressive disorder with
psychosis (n= 10), schizoaffective disorder (n= 10), substance-
induced psychosis (n = 4), schizophreniform disorder (n = 2),
delusional disorder (n = 1), organic psychosis (n = 1), brief
reactive psychosis (n = 1), and psychosis due to another medical
condition (n= 1). Demographic, diagnostic andmedication data
are provided in Table 1.
The majority of participants received APM monotherapy
(n = 81, 88%): risperidone (n = 28), aripiprazole (n = 19),
olanzapine (n = 16), quetiapine (n = 8), paliperidone (n = 4),
clozapine (n = 3), amisulpride (n = 2), ziprasidone (n = 2).
Eleven participants were prescribed dual APM: aripiprazole with
olanzapine (n = 5), risperidone (n = 1), or quetiapine (n = 2);
clozapine with amisulpride (n = 1), aripiprazole and quetiapine
(n = 1); and quetiapine with paliperidone (n = 1). Mean dosage
prescribed was 242 ± 186mg chlorpromazine equivalents.
Median APM exposure was 8months (IQR 7months). A range of
mood stabilizer, antidepressant and benzodiazepine medications
were also prescribed to some participants.
Themean BMIwas 25.7± 5.0 kg/m2 (males: 26.1± 4.4 kg/m2;
females 24.9 ± 5.7 kg/m2). Forty three participants had healthy
BMI (48%), with large proportions overweight (n = 31, 33%) or
obese (n = 16, 17%). One participant was underweight. Males
(60%) were more frequently overweight or obese compared to
females (34%), (X2 = 5.9, p = 0.01). The percent of females with
central obesity was numerically higher than for males (n = 22,
63% vs. n = 30, 52%), but this difference was not statistically
significant, X2 = 1.1, p= 0.2).
All participants met Goldberg’s criteria for plausible energy
intake reporting. Estimated energy intake (EEI) was significantly
and substantively higher than estimated energy requirements
(EER) (Z = −5.1, P < 0.001), with a median energy intake
excess of 1,837 kJ per day (IQR 5,365 kJ). Median energy intake
excess for males was 1,771 kJ per day (IQR 5,355 kJ), and
for females 1,837 kJ per day (IQR 5,196 kJ) (Table 2). There
was a significant difference for mean excess energy between
different APM (H = 15.7, p < 0.05). Excess energy consumption
was significantly higher in those prescribed APM polypharmacy
when compared to those prescribed amisulpride (p < 0.01)
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Age mean (SD) 21.5 (2.8) 21.2 (3.2) 21.4 (2.9)
Ethnicity n (%)
Europid 37 (64) 15 (42) 52 (56)
Asian 13 (21) 14 (40) 27 (29)
Maori/Pacific
Islander
5 (9) 1 (3) 6 (7)
Aboriginal/Torres
Strait Islander
1 (2) 2 (6) 3 (3)
Middle Eastern 1 (2) 2 (6) 3 (3)
African 0 (0) 1 (3) 1 (1)
South American 1 (2) 0 (0) 1 (1)
PHYSICAL ACTIVITY LEVEL
Sedentary 36 (62) 24 (68) 60 (64)
Light-Moderate 14 (24) 10 (29) 24 (26)
Active 8 (14) 1 (3) 9 (10)
ANTHROPOMETRIC MEASURES
Weight kg (SD) 82.4 (15.4) 66.8 (16.2) 76.5 (17.4)






1 (2) 0 (0) 1 (1)
Ideal weight
(18.5–24.9 kg/m2)
22 (38) 23 (66) 45 (49)
Overweight
(25–29.9 kg/m2 )
27 (46) 4 (11) 31 (33)
Obese (≥30.0
kg/m2 )
8 (14) 8 (23) 16 (17)
Waist
circumference





Ideal 28 (48) 13 (37) 41 (44)




Schizophrenia 25 (43) 7 (20) 32 (34)
Schizoaffective
disorder
5 (8) 5 (14) 10 (11)
Schizophreniform
disorder
0 (0) 2 (6) 2 (2)
Bipolar affective
disorder








6 (10) 9 (25) 15 (16)
Major depression
with psychosis
9 (16) 1 (3) 10 (11)
(Continued)




Delusion disorder 0 (0) 1 (3) 1 (1)
Organic psychosis 1 (2) 0 (0) 1 (1)
Brief reactive
psychosis
0 (0) 1 (3) 1 (1)
Psychosis due to
another medical




Risperidone 18 (31) 10 (29) 28 (30)
Aripiprazole 12 (21) 9 (26) 19 (20)
Quetiapine 4 (7) 4 (11) 8 (9)
Olanzapine 11 (19) 5 (14) 16 (17)
Clozapine 3 (5) 0 (0) 3 (3)
Amisulpride 1 (2) 1 (3) 2 (2)
Ziprasidone 1 (2) 1 (3) 2 (2)
Paliperidone 2 (3) 2 (6) 4 (4)
Antipsychotic
polypharmacy
6 (10) 5 (14) 11 (12)
Chlorpromazine
equivalent




median (IQR) 8.7 (7.5) 7.0 (5.7) 8.1 (6.9)
Antidepressant n (%)
Yes 15 (26) 12 (34) 27 (29)
Mood stabilizer
Yes 15 (26) 5 (14) 20 (22)
Benzodiazepine
Yes 4 (7) 1 (3) 5 (5)
ADDITIONAL MEDICATION
Metformin 1 (2) 1 (3) 2 (2)
and those prescribed risperidone (p < 0.05); those prescribed
olanzapine reported significantly higher excess energy intake
when compared to amisulpride (p< 0.01), risperidone (p= 0.02)
and aripiprazole (p = 0.04). There was no relationship between
medication dosage (chlorpromazine equivalents), or duration of
treatment with APM, and excess energy intake in this sample
(r = −0.004, p = 0.97; r = 0.02, p = 0.85). There was
no significant difference between those prescribed: one APM
only, APM polypharmacy, APM and mood stabilizer, APM and
antidepressant, or APM, mood stabilizer and antidepressant
(X2 = 3.8, p= 0.44). There was no significant difference between
all diagnoses within this sample (H = 2.3, p = 0.81), or major
subgroups: (i) schizophrenia spectrum, (ii) bipolar affective and
(iii) major depression with psychosis (H = 0.6, p= 0.90).
The sources of energy intake were, in descending order
of magnitude: grain foods (33%); discretionary foods (31%);
protein-rich foods (17%); added unsaturated fats and oils
including spreads (6%); dairy (milk, cheese and yogurt) (6%);
fruit (4%); and vegetables (3%). Mean daily serves of food groups
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were: grain foods 7.2± 3.7, discretionary foods 6.6± 5.8, protein
foods 3.7 ± 2.2, dairy foods 1.7 ± 1.4, fruit 1.7 ± 1.8, and
vegetables 2.8± 1.8 (Table 3).
Reported intakes were compared to Australian national
dietary recommendations. There was a significantly higher than
recommended intake of discretionary [t(92) = 6.4, p < 0.001].
In contrast, there were shortfalls in recommended intakes
of vegetables [t(92) = −13.4, p < 0.001], dairy [t(92) =
−6.5, p < 0.001], and unsaturated oils/spreads [t(34) = −14.9,
p < 0.001]. The majority of participants consumed grain-
containing foods as refined/processed products (81%); only 19%
consumed predominantly wholegrain products. The majority
of participants had shortfalls in the recommended intakes
of vegetables (86%), dairy (73%), and fruit (61%). The
recommended intake of discretionary food intake was exceeded
in 72% of participants.
DISCUSSION
To our knowledge, this is the first study to demonstrate
that youth with severe mental illness receiving APM and
other psychotropic medications have energy intakes that exceed
individual requirements by some 26% on average. Further,
excessive intakes of discretionary foods and refined grain-based
foods were evident, along with insufficient intakes of vegetables,
dairy and fruit. In combination with the sedentariness already
documented in people with psychosis (12), this excessive energy
intake is likely to contribute substantially to the rapid and
excessive weight-gain observed in the years after APM initiation.
The weight change dynamics paradigm of Hall and co-workers’
(30) predicts that every 100 kJ (24 kcal) intake excess will have
an eventual bodyweight change of 1 kg, with half this weight
change occurring within 1 year, and 95%weight change occurring
within 3 years. Applying this model to the excess daily energy
intake of 1,837 kJ (439 kcal) found in our study an eventual
bodyweight change of approximately 18 kg would be expected.
This can help explain the mean 20 kg weight gain that has been
observed in people receiving APM over the first 4 years of
treatment (4).
Whilst increasing physical activity is important for reducing
cardiovascular risk, and symptoms of depression and possibly
psychosis (31, 32), increased physical activity alone is unlikely
to adequately address this excessive energy imbalance: the
hypothetical 70 kg person would need to walk an additional 3.5 h
at 4 km/h or run for 1 h at 10 km/h each day to expend the
observed energy surplus (33). Therefore, reduction of energy
intake will be essential for preventing or reducing the weight gain
that follows APM initiation and their long-term use.
The higher excess in dietary energy intake found for
both APM polypharmacy and olanzapine is congruent with
the literature, with both of these having higher weight gain
potential compared to other second-generation APM (34, 35).
Treatment with a mood stabilizer and some antidepressant
medications can result in weight-gain. Given that our inclusion
criteria were young people with FEP receiving APM, with no
restriction on additional psychotropic medication prescription,
it was difficult to disentangle the effects of mood stabilizer
and antidepressant medication on dietary intake. Larger studies,
with set psychotropic medication criteria would allow greater
exploration of the effects of mood stabilizer and antidepressant
medications (with and without APM) on food and dietary
energy intake. Our study did not find a relationship between
APM dosage and excess dietary energy intake, although it
is conceivable that higher APM dosage would be associated
with greater appetite and therefore higher dietary energy
intake. Larger, appropriately designed studies would be needed
to confirm the effect that APM dosage has on dietary
intake.
Study limitations include the following: First, the cross-
sectional design means that prospective studies that measure
dietary intake at multiple time points are needed to confirm these
findings. Second, while the program aims to assess all young
people with FEP attending local health district services, there is
potential for more health conscious consumers to engage in a
dietary assessment. Third, there would be value in including a
matched comparison group of youth not receiving APMs. Ideally,
the comparator group would comprise sociodemographically-
matched youth with mental health disorders that do not
require treatment with APMs, such as depression and/or
anxiety. Though it is worthy to note that the reported energy
intake was substantially higher for both males and females
in this study compared to data from the general population
aged 19–30 years (36); 13,651 vs. 11,004 kJ/day for males,
and 11,513 vs. 7,863 kJ/day for women. This reinforces the
effects that impairments in executive function/reward system
and increased appetite have on energy intake in people with
psychosis. Fourth, important covariables such as symptom
level/functioning, economic status, education, marital status,
and metabolic/cardiovascular comorbidities, were not able to
be included in this analysis and should be considered for
future studies. Fifth, we could not determine if the nutritional
issues predated APM use. Dietary data in pre-medicated FEP
are required, but there are significant pragmatic obstacles to
collecting such data pre-treatment, due to the nature of untreated
severemental illness and compliance with nutritional assessment.
Sixth, dietary intake was estimated using the diet history method,
a subjective measure that could lead to selective underreporting.
The gold-standard objective biomarkers and the doubly labeled
water technique are expensive and intensive for both the
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Mean intake servings/day (SD) Statistical test ** Percent of participants
meeting national nutrition
recommendations (11).
Male Female Male (n = 22) Females (n = 13)
FOOD GROUPS
Grain foods 33 6 6 7.1 (3.8) 7.4 (3.8) t(92) = 2.5, p = 0.013 19% choosing predominantly
wholegrainProtein-based
foods
17 3 2.5 4.0 (3.2) 3.2 (1.9) t(92) = 2.8, p = 0.009
Dairy and
alternatives
6 2.5 2.5 1.8 (1.5) 1.6 (1.2) t(92) = −6.5,
p < 0.001***
27%
Vegetables 3 6 5 2.6 (1.8) 3.3 (1.8) t(92) = −13.4,
p < 0.001***
14%
Fruit 4 2 2 1.8 (2.2) 1.5 (1.2) t(92) = 1.6, p = 0.103 39%





31 0–3 0–2.5 7.6 (6.6) 4.8 (3.3) t(92) = 6.4,
p < 0.001***
27%
* Recommended serves per day including serving sizes are described in the Australian Guide to Healthy Eating (11).
** Mean intake of all participants compared to recommended serves/day.
*** Statistically significant after applying Bonferroni correction, with statistical significance set at p < 0.007.
researcher and participant, and therefore not feasible in all
studies. Studies that include these objective measures would help
confirm findings using subjective measures. The final limitation
is the conservative model used to calculate discretionary food
consumption; the benchmark was set at the upper limit
recommended, which would generally be reserved for those
with higher energy requirements. This may have underestimated
discretionary food intake. The dietary methodology did not
enable us to estimate intake of trans and saturated fats, and
free sugars, particularly relevant given the high intakes of
discretionary foods.
Comprehensive care of youth with severe mental illness
should incorporate lifestyle interventions to ameliorate
cardiometabolic risk factors. Weight-gain prevention
interventions implemented after APM initiation have larger
effect sizes, compared to weight-loss interventions in people
with enduring severe mental illness (37). Recognition of rapid
weight-gain and cardiometabolic health decline soon after APM-
initiation, together with evidence that lifestyle interventions in
early psychosis programs prevent such outcomes (22), underpin
the Healthy Active Lives (HeAL) Declaration (38), that defines
5-year targets for key lifestyle factors contributing to poor
cardiometabolic health in severe mental illness (www.iphys.
org.au). These include specific dietitian-led interventions for
weight management, which have been shown to be effective in
severe mental illness (37). Further exploration is also needed
for the use of adjunctive nutrients in people experiencing
FEP as a potential method of improving symptoms and
functioning (39).
While not explored in this study, it is important to note that
people at ultra-high risk for psychosis and APM naïve people
with FEP also have high rates of cardiometabolic abnormalities
(40). This may be explained, at least in part, by the impaired
executive functioning and reward system complicating the eating
process and increasing the preference for non-nutritious foods
high in sugar, salt and fat (14). Further exploration of the
effectiveness of weight-gain preventative measures in those at
ultra-high risk for psychosis and APM naïve people with FEP are
needed.
In summary, this cross-sectional study suggests excessive
consumption of discretionary and processed foods and
numerous shortfalls in essential quality requirements are likely
contributing not only to rapid weight gain, but also to other
longer-term health sequelae in people in the early stages of APM
treatment. Addressing the energy intake excesses observed in
people with FEP receiving APMmay assist in preventing weight-
gain in the early stages of APM treatment. Larger, prospective
studies, measuring dietary intake at multiple time points would
assist in providing a greater understanding of the dietary intake,
and its effects on health, in people with FEP.
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